How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine

/in ,

How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine Cynata Therapeutics, a Melbourne, Australia-based regenerative medicine company, is pioneering a new era in cell therapy with its Cymerus platform. Built on the foundation of induced pluripotent stem cell (iPSC) technology, Cynata’s approach offers a transformative alternative to traditional mesenchymal stem cell […]

Read more

Four in five Aussie asthma sufferers to breathe easier under new technology

/in , ,

Four in five Aussie asthma sufferers to breathe easier under new technology Tuesday, 29 April 2025 More than 2.2 million Australian people with asthma could benefit from life-changing digital inhaler technology which has the potential to save lives and ease the burden on Australia’s strained healthcare system.   Approximately 2.8 million Australians have a diagnosis […]

Read more

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease

/in ,

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease Melbourne, Australia; 7 April 2025 Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”,or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, today announced positive efficacy data observed in preclinical studies conducted with Cynata’s Cymerus™ iPSC[1]-derived MSCs[2] in models of ischaemic heart disease. MSCs […]

Read more

$2.6 million capital raise to progress roll-out of Hailie® Smartinhaler® platform in the US

/in ,

$2.6 million capital raise to progress roll-out of Hailie® Smartinhaler® platform in the US 18 Mar 2025 | Image source: adherium.com Adherium is pleased to announce that it has received firm commitments to raise $2,600,000, before costs, through the issuance of approximately 2,600,000 convertible notes. Investors will also receive 1 attaching option for every 2 […]

Read more

Meet 6 Aussie biotech startups vying to be the next CSL

/in ,

Meet 6 Aussie biotech startups vying to be the next CSL Australia’s first bioincubator, Jumar, opened its doors 10 months ago. Here are six standout startups that went through its inaugural program. Proxima Bio is one of the biotech startups going through the Jumar Bioincubator in Melbourne. Photograph Chris Hopkins In climbing parlance, a […]

Read more

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study

/in

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile LOS ANGELES, Dec. 19, 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. […]

Read more

Saluda Medical Appoints Jim Erickson as Chief Financial Officer

/in

Link Here Minneapolis, Minnesota – December 14, 2023 – Saluda Medical, Inc. (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven advanced closed-loop technologies, today announced the appointment of Jim Erickson as Chief Financial Officer (CFO). “I am thrilled to welcome Jim to Saluda and believe his […]

Read more